Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease

doi:10.16352/j.issn.1001-6325.2023.08.1317

Abstract

Abstract: Emerging evidence indicates that ferroptosis, an iron-dependent form of regulated cell death, plays a critical role in the pathological progression of non-alcoholic fatty liver disease (NAFLD). Ferroptosis involves in the pathogenesis of NAFLD and drugs targeting at ferroptosis by its inhibitors can alleviate the progression of NAFLD both in vitro and in vivo. Pharmacological inhibition of ferroptosis might be a potential strategy of NAFLD treatment.

Key words: non-alcoholic fatty liver disease(NAFLD), non-alcoholic steatohepatitis(NASH), ferroptosis, ferroptosis inhibitor

CLC Number:

R575.5

HAO Dandan, ZHANG Lei, BAI Chunying. Research progress of drugs targeting ferroptosis for the treatment of non-alcoholic fatty liver disease[J]. Basic & Clinical Medicine, 2023, 43(8): 1317-1321.

References 25

[1]	Yip TC, Lee HW, Chan WK, et al. Asian perspective on NAFLD-associated HCC[J]. J Hepatol, 2022,76:726-734.
[2]	Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022,185:2401-2421.
[3]	Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease[J]. Hepatology, 2012,55:77-85.
[4]	Yang Z, Wu J, Li X, et al. Association between dietary iron intake and the prevalence of nonalcoholic fatty liver disease: A cross-sectional study[J]. Medicine (Baltimore), 2019,98:e17613. doi:10.1097/MD.0000000000017613.
[5]	Beaton MD, Chakrabarti S, Levstik M, et al. Phase Ⅱ clinical trial of phlebotomy for non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2013,37:720-729.
[6]	Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis[J]. J Hepatol, 1999,31:421-429.
[7]	Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histolo-gical severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011,53:448-457.
[8]	Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019,10:449. doi:10.1038/s41419-019-1678-y.
[9]	Protchenko O, Baratz E, Jadhav S, et al. Iron chaperone poly rC binding protein 1 protects mouse liver from lipid peroxidation and steatosis[J]. Hepatology, 2021,73:1176-1193.
[10]	Yang Y, Chen J, Gao Q, et al. Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease[J]. Toxicology, 2020,445:152599. doi:10.1016/j.tox.2020.152599.
[11]	Gao G, Xie Z, Li EW, et al. Dehydroabietic acid improves nonalcoholic fatty liver disease through activating the Keap1/Nrf2-ARE signaling pathway to reduce ferroptosis[J]. J Nat Med, 2021,75:540-552.
[12]	Li X, Wang TX, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity[J]. Liver Int, 2020,40:1378-1394.
[13]	Gao H, Jin Z, Bandyopadhyay G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis[J]. Cell Metab, 2022,34:1201-1213.e5.
[14]	Qi J, Kim JW, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020,190:68-81.
[15]	Carlson BA, Tobe R, Yefremova E, et al. Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration[J]. Redox Biol, 2016,9:22-31.
[16]	Sztolsztener K, Chabowski A, Harasim-Symbor E, et al. Arachidonic acid as an early indicator of inflammation during non-alcoholic fatty liver disease development[J]. Biomolecules, 2020,10:1133. doi:10.3390/biom10081133.
[17]	Kim EH, Wong SW, Martinez J. Programmed necrosis and disease:We interrupt your regular programming to bring you necroinflammation[J]. Cell Death Differ, 2019,26:25-40.
[18]	Bailey AP, Koster G, Guillermier C, et al. Antioxidant role for lipid droplets in a stem cell niche of drosophila[J]. Cell, 2015,163:340-353.
[19]	Wei S, Qiu T, Wang N, et al. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis[J]. Environ Res, 2020,188:109824. doi:10.1016/j.envres.2020.109824.
[20]	Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4[J]. Eur J Pharmacol, 2021,908:174351. doi:10.1016/j.ejphar.2021.174351.
[21]	Saryusz-Wolska M, Szymańska-Garbacz E, Jabłkowski M, et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease[J]. Pol Arch Med Wewn, 2011,121:61-66.
[22]	Kung YA, Chiang HJ, Li ML, et al. Acyl-coenzyme a synthetase long-chain family member 4 is involved in viral replication organelle formation and facilitates virus replication via ferroptosis[J]. mBio, 2022,13:e0271721. doi:10.1128/mbio.02717-21.
[23]	Ma K, Chen Y, Liang X, et al. Inhibition of 5-lipoxygenase inhibitor zileuton in high-fat diet-induced nonalcoholic fatty liver disease progression model[J]. Iran J Basic Med Sci, 2017,20:1207-1212.
[24]	Jiang JJ, Zhang GF, Zheng JY, et al. Targeting mitochondrial ROS-mediated ferroptosis by quercetin alleviates high-fat diet-induced hepatic lipotoxicity[J]. Front Pharmacol, 2022,13:876550. doi:10.3389/fphar.2022.876550.
[25]	Ning K, Lu K, Chen Q, et al. Epigallocatechin gallate protects mice against methionine-choline-deficient-diet-induced nonalcoholic steatohepatitis by improving gut microbiota to attenuate hepatic injury and regulate metabolism[J]. ACS Omega, 2020,5:20800-20809.